Video interview with CEO Martin Vidaeus

Redwood Pharma CEO Martin Vidaeus discusses (English subtitles) the status of the RP101 Phase II clinical trial and the company's financial situation on June 19, 2019. See the following link.

For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ.) Tel: +46 (0) 70 232 29 29
E-mail: martin.vidaeus@redwoodpharma.com

About Redwood Pharma
Redwood Pharma develops ophthalmic products for unmet medical needs. The Company’s first project is the development of drug candidate RP101 with a known active substance against chronic dry eye in postmenopausal women who have moderate to severe symptoms. With the drug delivery platform IntelliGel the release of active substances is controlled. Through the use of IntelliGel, Redwood Pharma can also improve dosing of other established drugs. Redwood Pharma’s strength lies in formulation and early clinical development.  Revenues will be generated through licensing agreements with pharmaceutical companies that have capabilities to manufacture and sell commercial products worldwide.

Redwood Pharma AB (publ.) is listed on Spotlight Stock Market, a Swedish Multilateral Trading Facility (Ticker: REDW.ST, ISIN: SE008294789).

For more information visit: www.redwoodpharma.com